keyword
MENU ▼
Read by QxMD icon Read
search

Antipsychotic dosing

keyword
https://www.readbyqxmd.com/read/29667795/psychopharmacology
#1
Sahil Sekhon, George Kroumpouzos, John Koo
Most dermatologists evaluate and treat patients with psychological or psychiatric issues related to their skin disease. These patients often require psychopharmacologic therapies. Therefore, it is important for dermatologists to be familiar about psychopharmacologic treatments for diseases that fit into the overlap between psychiatry and dermatology. This review aims to provide a concise overview of psychopharmacology as it applies to dermatology. Psychotropic medications commonly used in psychodermatology, including antidepressants, antipsychotics, and anxiolytics, are reviewed; safety profile and dosing recommendations are discussed...
April 18, 2018: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29664808/trends-in-pharmacological-emergency-treatment-of-patients-suffering-from-schizophrenia-over-a-16-year-observation-period
#2
Monika Edlinger, Anna-Sophia Welte, Nursen Yalcin-Siedentopf, Georg Kemmler, Felix Neymeyer, W Wolfgang Fleischhacker, Alex Hofer
Patients suffering from schizophrenia are often treated in locked psychiatric units because of psychomotor agitation, hostility and aggressive behavior, or suicidality. Because of legal conditions, investigations on these acutely ill patients are difficult, and many studies do not represent 'real-life psychiatry'. This retrospective survey was conducted at the Department of Psychiatry, Psychotherapy and Psychosomatics of the Medical University, Innsbruck, Austria. Data were collected from the records of all adult inpatients suffering from a schizophrenia spectrum disorder according to the International Classification of Diseases, 10th ed...
April 16, 2018: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29659460/clozapine-titration-for-people-in-early-psychosis-a-chart-review-and-treatment-guideline
#3
Jacob S Ballon, Hera Ashfaq, Douglas L Noordsy
PURPOSE/BACKGROUND: The use of clozapine, particularly in young people, is often limited by early treatment-emergent adverse effects including drowsiness and lethargy. Concerns about adverse effects, medication adherence, and the need for blood monitoring often impede the use of clozapine in this population, leading to repeated trials of less effective medications. Current clozapine dosing recommendations are based on people further in the course of their illness and thus reflect different responsiveness and sensitivities to antipsychotic medication...
June 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29659206/effects-of-antipsychotics-on-secular-mortality-trends-in-patients-with-alzheimer-s-disease
#4
René Ernst Nielsen, Jan B Valentin, Annette Lolk, Kjeld Andersen
OBJECTIVE: To investigate secular changes in mortality rates between patients with Alzheimer's disease (AD) and the general population as well as changes in antipsychotic drug treatment and the association between drug treatment and mortality in patients with AD in Denmark during a 12-year study period. METHODS: This nationwide, retrospective cohort study identified all-cause mortality in all Danish patients with incident ICD-10-defined AD from 2000 through 2011...
April 3, 2018: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29652308/-clinical-psychopathological-aspects-of-therapeutic-effects-of-agomelatine-valdoxan-and-its-place-in-perfection-of-methods-of-therapy-of-postschizophrenic-depressive-disorders
#5
G P Panteleyeva, L I Abramova, T E Novozhenova, N V Subbotskaya, D V Tikhonov, P E Yumatova, I Yu Nikiforova
AIM: To determine a therapeutic effect of agomelatine (valdoxan) on post-schizophrenic depression (PSD), taking into account its psychopathological structure. MATERIAL AND METHODS: A total of 33 patients of both sexes (average age was 32.1 yrs) with symptoms of post-schizophrenic depression (F20.4 according to ICD-10) were examined by using clinical and psychometric methods in the dynamics of shift-like schizophrenia. HAMD-17, PANSS and CGI-S scales were applied...
2018: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29623228/response-after-infection-associated-rise-in-clozapine-levels-in-treatment-resistant-schizoaffective-disorder
#6
Nina H Grootendorst-van Mil, Anna R M Huiskens, Sieds Dieleman, Tom K Birkenhäger
The clinical management of patients with treatment-resistant psychotic disorders is still challenging despite years of extensive research. If first-line antipsychotic treatment proves ineffective, clozapine is considered golden standard. Herein, we report on a patient with schizoaffective disorder that initially showed no response to treatment with clozapine and ECT and therefore reached a therapeutic dead end. After an unintentional exposure to supratherapeutic clozapine levels, related to a pneumonia, a significant and persistent reduction of psychotic symptoms occurred...
2018: Case Reports in Psychiatry
https://www.readbyqxmd.com/read/29622043/aripiprazole-induced-sleep-related-eating-disorder-a-case-report
#7
Nobuyuki Kobayashi, Masahiro Takano
BACKGROUND: Sleep-related eating disorder is characterized by parasomnia with recurrent episodes of nocturnal eating or drinking during the main sleep period. Several drugs, including atypical antipsychotics, induce sleep-related eating disorder. However, aripiprazole has not previously been associated with sleep-related eating disorder. CASE PRESENTATION: A 41-year-old Japanese man visited our clinic complaining of depression. The patient was treated with sertraline, which was titrated up to 100 mg for 4 weeks...
April 5, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29619533/the-effects-of-cannabidiol-cbd-on-cognition-and-symptoms-in-outpatients-with-chronic-schizophrenia-a-randomized-placebo-controlled-trial
#8
Douglas L Boggs, Toral Surti, Aarti Gupta, Swapnil Gupta, Mark Niciu, Brian Pittman, Ashley M Schnakenberg Martin, Halle Thurnauer, Andrew Davies, Deepak C D'Souza, Mohini Ranganathan
RATIONALE: Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been evaluated for the treatment of cognitive impairments associated with schizophrenia (CIAS). OBJECTIVE: This study compared the cognitive, symptomatic, and side effects of CBD versus placebo in a clinical trial. METHODS: This study was a 6-week, randomized, placebo-controlled, parallel group, fixed-dose study of oral CBD (600 mg/day) or placebo augmentation in 36 stable antipsychotic-treated patients diagnosed with chronic schizophrenia...
April 5, 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29610916/should-this-patient-receive-prophylactic-medication-to-prevent-delirium-grand-rounds-discussion-from-beth-israel-deaconess-medical-center
#9
Anjala V Tess, Melissa L P Mattison, Joshua R Leo, Eileen E Reynolds
In 2015, the American Geriatrics Society released recommendations for prevention and management of postoperative delirium, based on a systematic literature review and evaluation of nonpharmacologic and pharmacologic approaches by an expert panel. The guidelines recommend an interdisciplinary focus on nonpharmacologic measures (reorientation, medication management, early mobility, nutrition, and gastointestinal motility) for prevention and consideration of this strategy for acute management. They also recommend optimizing nonopioid medication as a means to manage pain and avoiding benzodiazepines other than to treat substance withdrawal...
April 3, 2018: Annals of Internal Medicine
https://www.readbyqxmd.com/read/29609929/red-yeast-rice-ryr-supplementation-in-patients-treated-with-second-generation-antipsychotics
#10
Antonio Bruno, Gianluca Pandolfo, Manuela Crucitti, Giulia Maria Troili, Edoardo Spina, Rocco Antonio Zoccali, Maria Rosaria Anna Muscatello
OBJECTIVE: Second-generation antipsychotics (SGAs) have a negative impact on metabolic syndrome (MetS) risk factors for their effects on body weight and on metabolic parameters. Statins are widely used in the treatment of dyslipidemia; less is known on the ability of statins to treat SGAs-induced dyslipidemia, and nutraceutical approaches may represent promising strategies in SGAs-treated patients. Red Yeast Rice (RYR), the fermented product of the Aspergillaceae mold Monascus purpureus (red yeast) grown on white rice, has been shown to have a cholesterol-lowering effect which can be ascribed to monacolin K, although other active compounds may play a role management of hyperlipidemia...
April 2018: Complementary Therapies in Medicine
https://www.readbyqxmd.com/read/29605970/withdrawal-versus-continuation-of-long-term-antipsychotic-drug-use-for-behavioural-and-psychological-symptoms-in-older-people-with-dementia
#11
REVIEW
Ellen Van Leeuwen, Mirko Petrovic, Mieke L van Driel, An Im De Sutter, Robert Vander Stichele, Tom Declercq, Thierry Christiaens
BACKGROUND: Antipsychotic agents are often used to treat neuropsychiatric symptoms (NPS) in people with dementia although there is uncertainty about the effectiveness of their long-term use for this indication and concern that they may cause harm, including higher mortality. When behavioural strategies have failed and treatment with antipsychotic drugs is instituted, regular attempts to withdraw them have been recommended in guidelines. Physicians, nurses and families of older people with dementia may be reluctant to stop antipsychotics, fearing deterioration of NPS...
March 30, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29605187/antipsychotic-drugs-versus-cognitive-behavioural-therapy-versus-a-combination-of-both-in-people-with-psychosis-a-randomised-controlled-pilot-and-feasibility-study
#12
Anthony P Morrison, Heather Law, Lucy Carter, Rachel Sellers, Richard Emsley, Melissa Pyle, Paul French, David Shiers, Alison R Yung, Elizabeth K Murphy, Natasha Holden, Ann Steele, Samantha E Bowe, Jasper Palmier-Claus, Victoria Brooks, Rory Byrne, Linda Davies, Peter M Haddad
BACKGROUND: Little evidence is available for head-to-head comparisons of psychosocial interventions and pharmacological interventions in psychosis. We aimed to establish whether a randomised controlled trial of cognitive behavioural therapy (CBT) versus antipsychotic drugs versus a combination of both would be feasible in people with psychosis. METHODS: We did a single-site, single-blind pilot randomised controlled trial in people with psychosis who used services in National Health Service trusts across Greater Manchester, UK...
March 28, 2018: Lancet Psychiatry
https://www.readbyqxmd.com/read/29601407/effect-of-valproate-and-antidepressant-drugs-on-clozapine-metabolism-in-patients-with-psychotic-mood-disorders
#13
Donatella Marazziti, Lionella Palego, Laura Betti, Gino Giannaccini, Enrico Massimetti, Stefano Baroni, Antonio Ciapparelli, Antonio Lucacchini, Federico Mucci, Liliana Dell'Osso
BACKGROUND: The aim of the present study was to appraise retrospectively the influence of valproate (VPA) and antidepressants (ADs) on the steady-state plasma concentrations of clozapine (CLZ), the prototype of various second-generation antipsychotics (SGAs), norclozapine (NCLZ, its main metabolite), and their ratio (NCLZ/CLZ). METHODS: Sixty-seven psychotic patients with a prevalent diagnosis of bipolar disorder (BD) were studied. We then analyzed data altogether and subdivided them into four groups, according to pharmacological treatments: #1 CLZ (n=21), #2 CLZ plus antidepressants (ADs) (n=13), #3 CLZ plus VPA (n=16), and #4 CLZ plus ADs plus VPA (n=17)...
March 29, 2018: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/29582518/long-term-safety-and-effectiveness-of-brexpiprazole-in-japanese-patients-with-schizophrenia-a-52-week-open-label-study
#14
Jun Ishigooka, Shuichi Iwashita, Yoshihiro Tadori
AIMS: This study assessed the long-term safety, tolerability and maintenance of the therapeutic effect of brexpiprazole in Japanese patients with schizophrenia. METHODS: This 52-week, open-label, flexible-dose (1-4 mg/day) study included patients with schizophrenia who continued treatment from a short-term randomized placebo-controlled fixed-dose (1, 2, or 4 mg/day) trial and de novo patients who switched from other antipsychotics. RESULTS: A total of 282 patients (184 de novo and 98 rolled over from short-term trial) entered the 52-week treatment with brexpiprazole, and 150 (53...
March 26, 2018: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/29579587/a-systematic-review-of-clozapine-induced-myocarditis
#15
Brandi L Bellissima, Malcolm D Tingle, Aleksandar Cicović, Mohammed Alawami, Christopher Kenedi
BACKGROUND: Clozapine is an atypical antipsychotic that is beneficial to some patients who failed to have an adequate clinical response to other antipsychotic drugs. Its clinical use is limited due to several potentially fatal adverse reactions including myocarditis. Careful monitoring of patients on clozapine is required. METHODS: We conducted a systematic review of the literature on myocarditis associated with clozapine therapy. The search engines used to identify cases were MEDLINE, EMBASE, PsycINFO and Cochrane reviews...
May 15, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29575323/clozapine-reduces-nicotine-self-administration-blunts-reinstatement-of-nicotine-seeking-but-increases-responding-for-food
#16
Andrew R Abela, Zhaoxia Li, Anh D Lê, Paul J Fletcher
People with schizophrenia display significantly higher rates of smoking than the general population, which may be due to an interaction between nicotine and antipsychotic medication. While the conventional antipsychotic drug haloperidol sometimes increases cigarette smoking in patients with schizophrenia, there is some evidence suggesting that clozapine, an atypical antipsychotic drug, may reduce nicotine use in these patients. However, the effects of antipsychotic drugs like clozapine on aspects of nicotine self-administration and reinstatement have not been systematically examined...
March 25, 2018: Addiction Biology
https://www.readbyqxmd.com/read/29571966/effects-of-the-antipsychotics-haloperidol-clozapine-and-aripiprazole-on-the-dendritic-spine
#17
Manabu Takaki, Masafumi Kodama, Yutaka Mizuki, Hiroki Kawai, Bunta Yoshimura, Makiko Kishimoto, Shinji Sakamoto, Yuko Okahisa, Norihito Yamada
Three types of antipsychotics, typical (e.g. haloperidol), atypical (e.g. clozapine), and dopamine partial agonist (e.g. aripiprazole), are administered for treatment of schizophrenia. These antipsychotics have different efficacy and side-effect profiles. We investigated whether aripiprazole, clozapine, and haloperidol differentially regulate the dendritic spine through the AKT-GSK-3 beta cascade. Dissociated cortical neurons from Sprague-Dawley rats were prepared and cultured for 28 days. Aripiprazole, clozapine, or haloperidol was administered to the rat cortical neurons...
March 20, 2018: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29569082/long-acting-injectable-second-generation-antipsychotics-an-update-and-comparison-between-agents
#18
REVIEW
Michael W Jann, Scott R Penzak
Schizophrenia is a chronic medical condition with periods of remission and relapses over a patient's lifetime. Antipsychotic medications represent the mainstay of treatment for this disease. Long-acting injectable (LAI) formulations of antipsychotics are an attractive alternative to their oral counterparts, as they enhance patient adherence. A number of second-generation antipsychotics (SGAs) are available in LAI formulations. These include paliperidone, aripiprazole, olanzapine, and risperidone. This article reviews the most recently developed and approved of these formulations-aripiprazole monohydrate, aripiprazole lauroxil, and paliperidone palmitate...
March 22, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29564285/a-case-report-of-rapid-onset-hyponatremia-induced-by-low-dose-olanzapine
#19
Sethulakshmi Sreevalsam Anil, Badr Ratnakaran, Nisha Suresh
Hyponatremia has been reported with the use of psychotropic drugs. Olanzapine does not find much mention as a cause of hyponatremia in literature; however, it has been found to be the second most frequently reported atypical antipsychotic to cause it. We report a case of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion which occurred at a rapid onset following the administration of low-dose olanzapine during inpatient treatment of a patient with bipolar disorder. We would like to highlight our case for the need to be vigil about such fatal side complications apart from metabolic side effects of atypical antipsychotics...
October 2017: Journal of Family Medicine and Primary Care
https://www.readbyqxmd.com/read/29563800/efficacy-tolerability-and-safety-of-oral-paliperidone-extended-release-in-the-treatment-of-schizophrenia-a-24-week-open-label-prospective-switch-study-in-different-settings-in-taiwan
#20
Ching-Yen Chen, Tze-Chun Tang, Tzu-Ting Chen, Ya Mei Bai, Huei-Huang Tsai, Hou-Liang Chen, Chun-Jen Huang, Chih-Ken Chen, Chun-Chih Chen, Mei-Chun Hsiao, Chia-Yih Liu, Hong-Shiow Yeh, Nan-Ying Chiu, Cheng-Chen Hsiao, Cheng-Sheng Chen, Tung-Ping Su
Purpose: Paliperidone extended release (ER) is an oral psychotropic treatment formulated to release paliperidone at a controlled, gradually ascending rate. We evaluated the efficacy and safety of switching to paliperidone ER in Taiwanese patients with schizophrenia who were unresponsive or intolerant to previous antipsychotic therapy. Patients and methods: This was a 24-week, open-label, single-arm, multicenter, Phase IV trial. Based on consulting psychiatrists' judgment, patients were deemed eligible for the switch to paliperidone ER; the switch was achieved by cross-tapering, using a recommended starting dose of 6 mg...
2018: Neuropsychiatric Disease and Treatment
keyword
keyword
87834
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"